Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease

References

• King AMQ, Adams MJ, Carstens EB, editors. Virus Taxonomy: classification and nomenclature of viruses: Ninth report of the international committee on taxonomy of viruses, family- picornaviridae.  San Diego: Elsevier; 2012. p. 855–880.
   Google Scholar
• International Committee on Taxonomy of Viruses. ICTV 9th report. 2011. [cited 2018 Aug 18]. Available from: https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/234/picornaviridae
   Google Scholar
• Baggen J, Jan Thibaut HJ, Strating JRPM, et al. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368–381.
   PubMed Web of Science ®Google Scholar
• Klein M, Chong P. Is a multivalent hand, foot, and mouth disease vaccine feasible? Hum Vaccin Immunother. 2015;11(11):2688–2704.
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Bian L, et al. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):e75.
   PubMedGoogle Scholar
• Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med. 1999;341(13):929–935.
   PubMed Web of Science ®Google Scholar
• McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26(1):91–107.
   PubMed Web of Science ®Google Scholar
• Solomon T, Lewthwarte P, Perera D, et al. Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778–790.
   PubMed Web of Science ®Google Scholar
• WHO Regional Office for the Western Pacific. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). 2011. [cited 2018 Aug 18]. Available from: http://www.wpro.who.int/publications/PUB_9789290615255/en/
   Google Scholar
• Lyu K, Chen R. Achievements, challenges and prospects for the development of broadly protective multivalent vaccines and therapeutic antibodies against hand, foot and mouth disease. Sci Bull. 2015;60:1305–1315.
   Web of Science ®Google Scholar
• Koh WM, Badaruddin H, La H, et al. Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob Health. 2018;3(1):e000442.
   PubMed Web of Science ®Google Scholar
• Liu CC, Chow YH, Chong P, et al. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine. 2014;32(47):6177–6182.
   PubMed Web of Science ®Google Scholar
• Aswathyraj S, Arunkumar G, Alidjinou EK, et al. Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. Med Microbiol Immunol. 2016;205(5):397–407.
   PubMed Web of Science ®Google Scholar
• Chong P, Liu CC, Chow YH, et al. Review of enterovirus 71 vaccines. Clin Infect Dis. 2015;60(5):797–803.
   PubMed Web of Science ®Google Scholar
• Yee PTI, Laa Poh C. Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development. Virology. 2017 Jun;506:121–129.
   PubMed Web of Science ®Google Scholar
• Chou AH, Liu CC, Chang JY, et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody responses against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One. 2013;8(11):e79783.
   PubMed Web of Science ®Google Scholar
• Liu CC, Hwang CS, Yang WS, et al. Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques. PLoS One. 2014;9(9):e106756.
   PubMed Web of Science ®Google Scholar
• Chu SC, Wang ET, Liu DP. Is a monovalent vaccine against enterovirus 71 sufficient? A review of enterovirus 71 vaccine development based on enterovirus surveillance in Taiwan. J Formos Med Assoc. 2013;112(9):508–509.
   PubMed Web of Science ®Google Scholar
• Sickles GM, Mutterer M, Feorino P, et al. Recently classified types of Coxsackie virus, group A; behavior in tissue culture. Proc Soc Exp Biol Med. 1955;90(2):529–531.
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Yao X, et al. Coxsackievirus A16: epidemiology, diagnosis and vaccine. Hum Vaccin Immunother. 2014;10(2):360–367.
   PubMed Web of Science ®Google Scholar
• Yip CCY, Lau SKP, Woo PCY, et al. Human enterovirus 71 epidemics: what’s next? Emerg Health Threats J. 2013;6:19780.
   PubMedGoogle Scholar
• Lu QB, Zhang XA, Wo Y, et al. Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009–2011. PLoS One. 2012;7(12):e52073.
   PubMed Web of Science ®Google Scholar
• Wei SH, Huang YP, Liu MC, et al. An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis. 2011;11:346.
   PubMed Web of Science ®Google Scholar
• Downing C, Ramirez-Fort MK, Doan HQ, et al. Coxsackievirus A6 associated hand, foot and mouth disease in adults: clinical presentation and review of the literature. J Clin Virol. 2014;60(4):381–386.
   PubMed Web of Science ®Google Scholar
• Chung WH, Shih SR, Chang CF, et al. Clinicopathologic analysis of coxsackievirus a6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013;208(12):1968–1978.
   PubMed Web of Science ®Google Scholar
• Kaminska K, Martinetti G, Lucchini R, et al. Coxsackievirus A6 and hand, foot and mouth disease: three case reports of familial child-to-immunocompetent adult transmission and a literature review. Case Rep Dermatol. 2013;5(2):203–209.
   PubMedGoogle Scholar
• Tseng FC, Huang HC, Chi CY, et al. Epidemiological survey of enterovirus infections occurring in Taiwan between 2000 and 2005: analysis of sentinel physician surveillance data. J Med Virol. 2007;79(12):1850–1860.
   PubMed Web of Science ®Google Scholar
• Lo SH, Huang YC, Huang CG, et al. Clinical and epidemiologic features of Coxsackievirus A6 infection in children in northern Taiwan between 2004 and 2009. J Microbiol Immunol Infect. 2011;44(4):252–257.
   PubMedGoogle Scholar
• Ang LW, Koh BK, Chan KP, et al. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001–2007. Ann Acad Med Singapore. 2009;38(2):106–112.
   PubMed Web of Science ®Google Scholar
• Gaunt E, Harvala H, Österback R, et al. Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. J Gen Virol. 2015;96(Pt 5):1067–1079.
   PubMedGoogle Scholar
• Yang Q, Ding J, Cao J, et al. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10. J Med Virol. 2015;87(6):954–960.
   PubMed Web of Science ®Google Scholar
• Oberste MS, Peñaranda S, Maher K, et al. Complete genome sequences of all members of the species human enterovirus A. J Gen Virol. 2004;85(Pt 6):1597–1607.
   PubMed Web of Science ®Google Scholar
• Bessaud M, Razafindratsimandresy R, Nougairède A, et al. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS One. 2014;9:e90624.
   PubMed Web of Science ®Google Scholar
• Mizuta K, Abiko C, Aoki Y, et al. Molecular epidemiology of Coxsackievirus A16 strains isolated from children in Yamagata, Japan between 1988 and 2011. Microbiol Immunol. 2013;57(5):400–405.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhu R, Yang Y, et al. Phylogenetic analysis of the major causative agents of hand, foot and mouth disease in Suzhou City, Jiangsu province, China, in 2012–2013. Emerg Microbes Infect. 2015;4(2):e12.
   PubMedGoogle Scholar
• Xu M, Su L, Cao L, et al. Genotypes of the enterovirus causing hand foot and mouth disease in Shanghai, China, 2012–2013. PLoS One. 2015;10(9):e0138514.
   PubMed Web of Science ®Google Scholar
• Yu W, Xu H, Yin C. Molecular epidemiology of human coxsackievirus A16 strains. Biomed Rep. 2016;4(6):761–764.
   PubMed Web of Science ®Google Scholar
• Hu YF, Yang F, Du J, et al. Complete genome analysis of coxsackievirus A2, A4, A5, and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A. J Clin. 2011;49(7):2426–2434.
   Google Scholar
• Zhang T, Du J, Xue Y, et al. Epidemics and frequent recombination within species in outbreaks of human enterovirus B-associated hand, foot and mouth disease in Shandong China in 2010 and 2011. PLoS One. 2013;8(6):e67157.
   PubMed Web of Science ®Google Scholar
• Liu VV, Wu S, Xiong Y, et al. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot and mouth disease in central China. PLoS One. 2014;9(4):e96051.
   PubMed Web of Science ®Google Scholar
• Feng X, Guan W, Guo Y, et al. A novel recombinant lineage’s contribution to the outbreak of coxsackievirus A6-associated hand, foot and mouth disease in Shanghai, China, 2012–2013. Sci Rep. 2015;5:11700.
   PubMed Web of Science ®Google Scholar
• Liang ZL, Mao Q, Gao F, et al. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med. 2013;7:111–121.
   PubMed Web of Science ®Google Scholar
• Cheng A, Fung CP, Liu CC, et al. A phase 1, randomized, open-label study to evaluate the safety and immunogenicity of enterovirus 71 vaccine. Vaccine. 2013;31(20):2471–2476.
   PubMed Web of Science ®Google Scholar
• China Food and Drug Administration. Announcement on licensed drugs approved. 2016. No.4. 2016-Jan-15 [cited 2018 Aug 18]. Available from: http://samr.cfda.gov.cn/WS01/CL0087/142000.html; 2016. No.5. 2017-Jan-05, [cited 2018 Aug 18]. Available from: http://samr.cfda.gov.cn/WS01/CL1283/168353.html; 2017. No.21. 2017-Mar-22 [cited 2018 Aug 18]. Available from: http://www.hubfda.gov.cn/zxbw/gztz/eslb/30764.htm.
   Google Scholar
• Jin P, Li J, Zhang X, et al. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6–35 months. Hum Vaccin Immunother. 2016;12(4):916–921.
   PubMed Web of Science ®Google Scholar
• Wei M, Meng F, Wang S, et al. 2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215(1):56–63.
   PubMed Web of Science ®Google Scholar
• Zhu W, Jin P, Li JX, et al. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. Expert Rev Vaccines. 2017;16(9):945–949.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zeng G, Chu K, et al. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation. Hum Vaccin Immunother. 2018;14(6):1517–1523.
   PubMed Web of Science ®Google Scholar
• Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828.
   PubMed Web of Science ®Google Scholar
• Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in health children. N Engl J Med. 2014;370(9):829–837.
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Gao R, et al. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012;86(22):11967–11976.
   PubMed Web of Science ®Google Scholar
• Chong P, Guo MS, Lin FH, et al. Immunological and biochemical characterization of coxsackievirus A16 viral particles. PLoS One. 2012;7(11):e49973.
   PubMed Web of Science ®Google Scholar
• Cai Y, Liu Q, Huang X, et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine. 2013;31(18):2215–2221.
   PubMed Web of Science ®Google Scholar
• Yang E, Cheng C, Zhang Y, et al. Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccin Immunother. 2014;10(5):1266–1273.
   PubMed Web of Science ®Google Scholar
• Li J, Chang J, Liu X, et al. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol. 2014;95(Pt 5):1083–1093.
   PubMedGoogle Scholar
• An W Q, Su Z G, Wen Pan R, et al. The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems. Hum Vaccin Immunother. 2014;10(3):628–639.
   PubMed Web of Science ®Google Scholar
• Shen C, Liu Q, Zhou Y, et al. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34(41):5005–5012.
   PubMed Web of Science ®Google Scholar
• Lin CW, Liu CC, Lu TC, et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. Biomed Res Int. 2014;2014:670506.
   PubMed Web of Science ®Google Scholar
• Cai Y, Ku Z, Liu Q, et al. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine. 2014;32(21):2406–2412.
   PubMed Web of Science ®Google Scholar
• Sun S, Jiang L, Liang Z, et al. Evaluation of monovalent and bivalent vaccines against lethal enterovirus 71 and Coxsackie virus A16 infection in newborn mice. Hum Vaccin Immunother. 2014;10(10):2885–2895.
   PubMed Web of Science ®Google Scholar
• Li M, Duan Y, Yang X, et al. Intradermal injection of a fractional dose of an inactivated HFMD vaccine elicits similar protective immunity to intramuscular inoculation of a full dose of an Al(OH)3-adjuvanted vaccine. Vaccine. 2017;35(30):3709–3717.
   PubMed Web of Science ®Google Scholar
• Yang L, Liu Y, Li S, et al. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice. Vaccine. 2016;34(48):5938–5945.
   PubMed Web of Science ®Google Scholar
• Caine EA, Fuchs J, Das SC, et al. Efficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and Coxsackieviruses A16 and A6 in mice. Viruses. 2015;7(11):5919–5932.
   PubMed Web of Science ®Google Scholar
• Liu CC, Guo MS, Wu SR, et al. Immunological and biochemical characterizations of Coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58–66.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Zhang X, et al. Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques. Virology. 2017;500:198–208.
   PubMed Web of Science ®Google Scholar
• Xie ZH, Zhang YZ, Yan YS, et al. Preliminary study on recurrence with viruses causing hand foot and mouth disease. JI BING JIAN CE. 2013;28(9):735–739. Chinese.
   Google Scholar
• Chung YC, Huang JH, Lai CW, et al. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol. 2006;12(6):921–927.
   PubMed Web of Science ®Google Scholar
• Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26(15):1855–1862.
   PubMed Web of Science ®Google Scholar
• Lin YL, Yu CI, Hu YC, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30(7):1305–1312.
   PubMed Web of Science ®Google Scholar
• Li HY, Han JF, Qin CF, et al. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31(32):3281–3287.
   PubMed Web of Science ®Google Scholar
• Ye X, Ku Z, Liu Q, et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol. 2014;88(1):72–81.
   PubMed Web of Science ®Google Scholar
• Tsou YL, Lin YW, Shao HY, et al. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS Negl Trop Dis. 2015;9(4):e0003692.
   PubMed Web of Science ®Google Scholar
• Yan Q, Wu L, Chen L, et al. Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges. Vaccine. 2016;34(35):4196–4204.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yan K, Feng Y, et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30(47):6642–6648.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li HY, Han JF, et al. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol. 2013;97(24):10445–10452.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu Q, Ku Z, et al. Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice. Antiviral Res. 2016;129:47–51.
   PubMed Web of Science ®Google Scholar
• Shen C, Ku Z, Zhou Y, et al. Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. Vaccine. 2016;34(34):4025–4031.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shen C, Zhang C, et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res. 2016;132:165–169.
   PubMed Web of Science ®Google Scholar
• Zhang W, Dai W, Zhang C, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang C, Liu Q, et al. A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antiviral Res. 2018;152:124–130.
   PubMed Web of Science ®Google Scholar
• Gong M, Zhu H, Zhou J, et al. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol. 2014;88(11):6444–6452.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li HY, Han JF, et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci Rep. 2015;5:7878.
   PubMed Web of Science ®Google Scholar
• Xu L, He D, Yang L, et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci Rep. 2015;5:12973.
   PubMed Web of Science ®Google Scholar
• Tam PE. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 2006;19(2):133–146.
   PubMed Web of Science ®Google Scholar
• Henke A, Jarasch N, Wutzler P. Vaccination procedures against Coxsackievirus-induced heart disease. Expert Rev Vaccines. 2003;2(6):805–815.
   PubMedGoogle Scholar
• Park JH, Kim DS, Cho YJ, et al. Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis. Vaccine. 2009;27(13):1974–1983.
   PubMed Web of Science ®Google Scholar
• Zhang L, Parham NJ, Zhang F, et al. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis. Vaccine. 2012;30(13):2301–2308.
   PubMed Web of Science ®Google Scholar
• Liu CC, Chang HW, Yang G, et al. Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. J Virol Methods. 2011;176(1–2):60–68.
   PubMed Web of Science ®Google Scholar
• Foo DG, Ang RX, Alonso S, et al. Identification of immunodominant VP1 linear epitope of enterovirus 71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in western blots. Clin Microbiol Infect. 2008;14(3):286–288.
   PubMed Web of Science ®Google Scholar
• Foo DG, Alonso S, Phoon MC, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125(1):61–68.
   PubMed Web of Science ®Google Scholar
• Chang HW, Liu CC, Lin MH, et al. Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods. 2011;173(2):189–195.
   PubMed Web of Science ®Google Scholar
• Liu CC, Chou AH, Lien SP, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29(26):4362–4372.
   PubMed Web of Science ®Google Scholar
• Kirk K, Poh CL, Fecondo J, et al. Cross-reactive neutralizing antibody epitopes against enterovirus 71 identified by an in silico approach. Vaccine. 2012;30(49):7105–7110.
   PubMed Web of Science ®Google Scholar
• Xu L, He D, Li Z, et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics. 2014;4(5):498–513.
   PubMed Web of Science ®Google Scholar
• Lee H, Cifuente JO, Ashley RE, et al. A strain-specific epitope of enterovirus 71 identified by cryo-electron microscopy of the complex with fab from neutralizing antibody. J Virol. 2013;87(21):11363–11370.
   PubMed Web of Science ®Google Scholar
• Plevka P, Lim PY, Perera R, et al. Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc Natl Acad Sci U S A. 2014;111(6):2134–2139.
   PubMed Web of Science ®Google Scholar
• Kiener TK, Jia Q, Meng T, et al. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved “knob” region of VP3 protein. PLoS Negl Trop Dis. 2014;8(5):e2895.
   PubMed Web of Science ®Google Scholar
• Jia Q, Ng Q, Chin W, et al. Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity. Sci Rep. 2017;7:46402.
   PubMed Web of Science ®Google Scholar
• Jiang L, Fan R, Sun S, et al. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. Vaccine. 2015;33(48):6596–6603.
   PubMed Web of Science ®Google Scholar
• Huang KY, Chen MF, Huang YC, et al. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nat Commun. 2017;8(1):762.
   PubMedGoogle Scholar
• Shi J, Huang X, Liu Q, et al. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013;31(17):2130–2136.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang C, Zhou Y, et al. A 3.0-angstrom resolution cryo-electron microscopy structure and antigenic sites of Coxsackievirus A6-like particles. J Virol. 2018;92(2):e01257–17.
   PubMed Web of Science ®Google Scholar
• Xu L, Zheng Q, Li S, et al. Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nat Commun. 2017;8(1):505.
   PubMed Web of Science ®Google Scholar
• Dang M, Wang X, Wang Q, et al. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell. 2014;5(9):692–703.
   PubMed Web of Science ®Google Scholar
• Wang X, Peng W, Ren J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19(4):424–429.
   PubMed Web of Science ®Google Scholar
• Lee BY, Wateska AR, Bailey RR, et al. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine. 2010;28(49):7731–7736.
   PubMed Web of Science ®Google Scholar
• Li L, Yin H, An Z, et al. Considerations for developing an immunization strategy with enterovirus 71 vaccine. Vaccine. 2015;33(9):1107–1112.
   PubMed Web of Science ®Google Scholar